REGN-Cov2 for the treatment of COVID-19
Rapid Collaborative Review
16.08.2021 (revised 03.09.2021)
08.07.2021 (revised 03.09.2021)
Remdesivir for the treatment of COVID-19
Assessment discontinued due to unexpected changes to the timelines of the EU regulatory procedure.
Following CHMP opinion, EUnetHTA’s PICO is published in the project plan.
AEMPS, JAZMP, HIS
HAS, AOTMiT, HVB, RER
Observer: HTA Department/EC Ukraine
Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues
Patient Input – Diabetes Type 1
AEMPS, SNHTA, NVD, INFARMED, AOTMiT,
24.05.2021 (revised 20.01.2022)
12.06.2020 (revised 25.11.2020)
* EUnetHTA JA3 will not be accepting any further Letters of Intent with regard to new pharma Joint Assessments through the end of Joint Action 3 on 31st May, 2021.
= Patients have been involved in the assessment.
OT – Other Technologies
PT – Pharmaceutical Technologies
CA – Collaborative Assessment
JA – Joint Assessment
All EUnetHTA JA3 Assessment reports are published under the Creative Commons license CC-BY-NC.
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.